Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.5 GBX | 0.00% | 0.00% | -8.81% |
Apr. 02 | Roadside shares suspended; Adnams looks for funds | AN |
Mar. 26 | EARNINGS: CAB Payments profit drops, Life Science REIT cuts dividend | AN |
Valuation
Fiscal Period: November | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 101.8 | 66.45 | 50.38 | 78.42 | 57 | 46.27 | 46.27 |
Enterprise Value (EV) 1 | 102.4 | 64.05 | 50.38 | 78.42 | 57 | 50.52 | 36.97 |
P/E ratio | -216 x | -4.29 x | -2.38 x | 21.9 x | -14.2 x | -20.9 x | 259 x |
Yield | 0.65% | - | - | - | - | - | - |
Capitalization / Revenue | 1.22 x | 0.85 x | - | - | - | 1.15 x | 1.21 x |
EV / Revenue | 1.23 x | 0.82 x | - | - | - | 1.15 x | 0.97 x |
EV / EBITDA | 12.8 x | 8.9 x | - | - | - | 14.4 x | 9.99 x |
EV / FCF | 23.1 x | 85.3 x | - | - | - | - | 37 x |
FCF Yield | 4.34% | 1.17% | - | - | - | - | 2.7% |
Price to Book | 1.48 x | 1.35 x | - | - | - | 1.48 x | 1.7 x |
Nbr of stocks (in thousands) | 42,863 | 42,871 | 42,880 | 44,685 | 44,706 | 44,706 | 44,706 |
Reference price 2 | 2.375 | 1.550 | 1.175 | 1.755 | 1.275 | 1.035 | 1.035 |
Announcement Date | 3/19/19 | 7/27/20 | 3/30/21 | 4/25/22 | 3/23/23 | 3/26/24 | - |
Income Statement Evolution (Annual data)
Fiscal Period: November | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales 1 | 83.34 | 78.4 | - | - | - | 43.78 | 38.3 |
EBITDA 1 | 8.015 | 7.2 | - | - | - | 3.497 | 3.7 |
EBIT 1 | 4.6 | 1.8 | - | - | - | 1.263 | 1.9 |
Operating Margin | 5.52% | 2.3% | - | - | - | 2.88% | 4.96% |
Earnings before Tax (EBT) 1 | 0.017 | -14.5 | - | - | - | -1.821 | 0.4 |
Net income 1 | -0.488 | - | -21.13 | 3.531 | -3.978 | -2.385 | 0.2 |
Net margin | -0.59% | - | - | - | - | -5.45% | 0.52% |
EPS 2 | -0.0110 | -0.3610 | -0.4930 | 0.0800 | -0.0900 | -0.0540 | 0.004000 |
Free Cash Flow 1 | 4.441 | 0.751 | - | - | - | - | 1 |
FCF margin | 5.33% | 0.96% | - | - | - | - | 2.61% |
FCF Conversion (EBITDA) | 55.41% | 10.43% | - | - | - | - | 27.03% |
FCF Conversion (Net income) | - | - | - | - | - | - | 500% |
Dividend per Share | 0.0154 | - | - | - | - | - | - |
Announcement Date | 3/19/19 | 7/27/20 | 3/30/21 | 4/25/22 | 3/23/23 | 3/26/24 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: November | 2019 S1 | 2023 S1 | 2023 S2 |
---|---|---|---|
Net sales 1 | 38.21 | - | 23.51 |
EBITDA 1 | 2.291 | - | 3.15 |
EBIT 1 | - | - | 2.054 |
Operating Margin | - | - | 8.74% |
Earnings before Tax (EBT) | - | - | - |
Net income | - | -2.868 | - |
Net margin | - | - | - |
EPS | -0.0370 | - | - |
Dividend per Share | - | - | - |
Announcement Date | 7/9/19 | 8/30/23 | 3/26/24 |
Balance Sheet Analysis
Fiscal Period: November | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net Debt 1 | 0.62 | - | - | - | - | 7.2 | - |
Net Cash position 1 | - | 2.4 | - | - | - | - | 9.3 |
Leverage (Debt/EBITDA) | 0.0771 x | - | - | - | - | 1.469 x | - |
Free Cash Flow 1 | 4.44 | 0.75 | - | - | - | - | 1 |
ROE (net income / shareholders' equity) | 4.22% | -4.85% | - | - | - | 1.6% | 4.8% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | 1.610 | 1.150 | - | - | - | 0.7000 | 0.6100 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | 3.38 | - | - | - | - | 2 | 0.5 |
Capex / Sales | 4.05% | - | - | - | - | 4.26% | 1.31% |
Announcement Date | 3/19/19 | 7/27/20 | 3/30/21 | 4/25/22 | 3/23/23 | 3/26/24 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.81% | 57.63M | |
+11.17% | 322B | |
+24.75% | 216B | |
+2.41% | 149B | |
+10.65% | 56.27B | |
+8.71% | 32.13B | |
-4.57% | 27.45B | |
+103.03% | 22.62B | |
+20.22% | 19.55B | |
+0.04% | 14.61B |
- Stock Market
- Equities
- KBT Stock
- Financials K3 Business Technology Group plc